Zydus Cadila seeks Emergency Use Authorisation for its DNA vaccine, ZyCoV-D, for 12 years and above in India.
Zydus Cadila has applied for Emergency Use Authorisation (EUA) nod from the Drugs Controller General of India (DCGI) for the launch of its DNA vaccine, ZyCoV-D, for 12 years and above. The company said that its vaccine has completed the third phase of trial.
If DGCA grants approval, ZyCoV-D will join Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik V vaccines to be authorized for emergency use in India.
According to the company’s claim, ZyCoV-D showed safety and efficacy during a late-stage trial . It involved more than 28,000 volunteers across the country. This included 1,000 subjects in the 12-18 year age group.
Zydus said that the study was carried out during the peak of second wave in India. It said that the drug is effective against the mutant strains especially the Delta variant which is prevalent in India.
